Vaniprevir

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Vaniprevir
Vaniprevir.svg
Names
IUPAC name
(1R,21S,24S)-21-tert-butyl-N-((1R,2R)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.207.830
UNII
Properties
C38H55N5O9S
Molar mass 757.94 g/mol
Appearance White Powder
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing.[1]

In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.[2][3]

References[edit]

  1. ^ McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ (March 2010). "Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor". J. Med. Chem. 53 (6): 2443–63. doi:10.1021/jm9015526. PMID 20163176. 
  2. ^ "First recommendation for HCV drug vaniprevir, in Japan". datamonitorhealthcare.com. September 25, 2014. 
  3. ^ "New Drugs Approved" (PDF). Pharmaceuticals and Medical Devices Agency.